Lisinopril Dihydrate: Long-Acting ACE Inhibitor for Hypertension Research

Executive Summary:
Lisinopril dihydrate is a potent, long-acting ACE inhibitor with an IC₅₀ of 4.7 nM under standard assay conditions, enabling precise inhibition of angiotensin converting enzyme activity (Tieku & Hooper, 1992). It is a lysine analogue of MK 421 and is widely used in hypertension, heart failure, acute myocardial infarction, and diabetic nephropathy models (APExBIO). Lisinopril dihydrate reduces blood pressure by decreasing angiotensin II and aldosterone levels, while increasing plasma renin activity. The compound is a water-soluble solid (≥2.46 mg/mL with warming/ultrasonics), supplied at ≥98% purity, and is best stored desiccated at room temperature (APExBIO). Benchmarking studies confirm its selectivity for ACE over other peptidases, minimizing off-target effects in preclinical research (Tieku & Hooper, 1992).

Biological Rationale

Angiotensin converting enzyme (ACE; EC 3.4.15.1) is a zinc metallopeptidase critical for converting angiotensin I to angiotensin II, a potent vasoconstrictor (Tieku & Hooper, 1992). Angiotensin II increases blood pressure, aldosterone secretion, and fluid retention, forming the core of the renin-angiotensin system (RAS). Inhibition of ACE is a validated strategy for lowering blood pressure and reducing cardiovascular risk. Lisinopril dihydrate is a lysine derivative structurally related to MK 421, engineered for high specificity and prolonged action (APExBIO). Unlike earlier ACE inhibitors, lisinopril dihydrate is not a prodrug and does not require metabolic activation. Its high water solubility and chemical stability make it suitable for both in vitro and in vivo research. The compound is routinely applied in translational models of hypertension, heart failure, myocardial infarction, and diabetic nephropathy (related article).

Mechanism of Action of Lisinopril dihydrate

Lisinopril dihydrate competitively inhibits ACE by binding to its active site, preventing the enzymatic conversion of angiotensin I to angiotensin II (Tieku & Hooper, 1992). This action decreases circulating angiotensin II and aldosterone, resulting in vasodilation and reduced sodium and water retention. The molecular formula is C₂₁H₃₅N₃O₇, with a molecular weight of 441.52 g/mol. Lisinopril dihydrate shows an IC₅₀ value of 4.7 nM in standard ACE inhibition assays. The compound does not significantly inhibit other cell surface metallopeptidases, such as aminopeptidase N (AP-N; EC 3.4.11.2), aminopeptidase A (AP-A; EC 3.4.11.7), or aminopeptidase W (AP-W; EC 3.4.11.16), at concentrations selective for ACE (Tieku & Hooper, 1992). This selectivity reduces potential confounding effects in research models involving peptide metabolism.

Evidence & Benchmarks

• Lisinopril dihydrate achieves a 50% inhibition (IC₅₀) of purified ACE at 4.7 nM in standard buffer (pH 8.3, 25°C; Tieku & Hooper, 1992, DOI).
• The compound displays minimal inhibitory activity against AP-N, AP-A, and AP-W at up to 10 μM, confirming high selectivity (Tieku & Hooper, 1992, DOI).
• Lisinopril dihydrate is soluble in water at concentrations ≥2.46 mg/mL with gentle warming and ultrasonic treatment (APExBIO).
• Purity confirmed at ≥98% by mass spectrometry and NMR analysis per batch (see product COA: APExBIO).
• In vivo, lisinopril administration leads to significant reductions in plasma angiotensin II and aldosterone, with compensatory increases in plasma renin (related article).

Applications, Limits & Misconceptions

Lisinopril dihydrate is the reference long-acting ACE inhibitor for preclinical hypertension, heart failure, myocardial infarction, and nephropathy models (related article). Its high selectivity and solubility make it amenable to biochemical, cellular, and animal studies. The product is particularly valued for dissecting RAS pathway dynamics and for pharmacodynamic benchmarking against other ACE inhibitors. For a deeper mechanistic discussion, see "Lisinopril Dihydrate: Precision Long-Acting ACE Inhibitor", which details comparative workflows; this article extends that by providing new selectivity data and storage parameters. Recent insights reveal no significant cross-inhibition with AP-N, AP-A, or AP-W at pharmacologically relevant doses, minimizing off-target confounds (Tieku & Hooper, 1992).

Common Pitfalls or Misconceptions

• Not a prodrug: Lisinopril dihydrate does not require hepatic activation, unlike some earlier ACE inhibitors (APExBIO).
• No significant effect on aminopeptidases: The compound does not meaningfully inhibit AP-N, AP-A, or AP-W at research concentrations (Tieku & Hooper, 1992).
• Limited ethanol solubility: Lisinopril dihydrate is insoluble in ethanol; water is required for solution preparation (APExBIO).
• Instability in solution over time: Long-term storage of aqueous solutions is not recommended; prepare fresh as needed.
• Does not inhibit all RAS components: Selective for ACE; does not block renin or angiotensin receptor pathways directly.

Workflow Integration & Parameters

Lisinopril dihydrate is used as a solid or in aqueous solution for in vitro and in vivo experiments. Prepare solutions in water at ≥2.46 mg/mL, using gentle warming and ultrasonic agitation if needed. Avoid ethanol-based solvents due to poor solubility. For molecular and cellular assays, standard concentrations range from 1 nM to 10 μM depending on endpoint. Store the dry compound desiccated at room temperature; ship on blue ice for stability. Avoid long-term storage of working solutions—prepare fresh before use. Quality is verified by mass spectrometry and NMR for each lot. For expanded troubleshooting and advanced applications, see "Lisinopril Dihydrate: Mechanistic Precision and Strategic..."; this article updates storage and selectivity parameters not previously detailed.

Conclusion & Outlook

Lisinopril dihydrate, as provided by APExBIO, is a gold-standard, long-acting ACE inhibitor with exceptional selectivity and reproducibility for hypertension and cardiovascular research. Its robust inhibition profile, high solubility, and purity (≥98%) enable reliable dissection of the renin-angiotensin system. Proper selection and handling of this compound can minimize experimental confounds and accelerate translational discoveries. Ongoing research continues to refine its applications in complex disease models and precision medicine.